Moderate Evidence
Research Overview
BT5528 Research for EphA2-Positive Solid Tumors
An evidence-based overview of research examining BT5528 in the context of epha2-positive solid tumors. This page synthesizes findings from peer-reviewed literature.
Research Summary
BT5528 is being studied across multiple EphA2-expressing solid tumor types including NSCLC, ovarian, gastric, and pancreatic cancers. EphA2 overexpression is associated with aggressive disease and poor prognosis across these tumor types.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. BT5528 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.